tradmap

LIXT Financials LIXTE BIOTECHNOLOGY HOLDINGS, INC.

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Financial health

  • Operating income covered interest expense -557.7× in the latest year, up from -889.1× 5 years ago.
Revenue & net income
-$14M -$7M $200000 $0 2013 2014 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
-1426% -713% 0% 2013 2014 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Free cash flow (CFO − capex)
$0 $1 $1 2013 2014 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $3M $5M 2013 2014 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$7M $1M $10M $0 2013 2014 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 -$6M
2024 -$4M
2023 -$5M $4M
2022 -$6M $5M
2021 -$7M $5M
2020 -$3M $5M
2019 -$2M $3M
2018 -$2M $4M
2017 -$2M $1M
2016 -$2M $199929
2015 $200000 -$3M 0.0% -1323.2% $25281
2014 -$3M $44411
2014 -$14M $115440
2013 $0 -$1M $475019
2013 $0 -$13M

Frequently asked questions

Is LIXT growing its revenue and profit?

See the revenue and net-income charts above for LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s multi-year trend.

How much debt does LIXT have?

As of FY2025, LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported — of total debt against — of cash; operating income covered interest expense -557.7×.

What is LIXT's profit margin?

In FY2025, gross margin was —, operating margin —, and net margin —.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.